Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04079790).
- Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00492622).
- Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05885763).
- Pharmacokinetics of JULUCA in Hemodialysis: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of JULUCA in Hemodialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04431518).
- Pharmacokinetics of Linezolid in Children With Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Linezolid in Children With Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00625703).
- Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386): primary endpoint results, effect estimate with confidence…
- Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pharmacokinetics of Omadacycline in Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Omadacycline in Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04460586).
- Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01179919).
- Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00555061).
- Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01380184).
- Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Given With Or Without Food.: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Given With Or Without Food.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01667796).
- Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment: primary endpoint results, effect estimate…
- Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (MT-3724_NHL_003): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003): primary endpoint results, effect…
- Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02232178).
- Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD): primary endpoint results, effect estimate with confidence…
- Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Pharmacological Effects of Crushing Prasugrel in STEMI Patients: Complete Statistical AnalysisIndependent statistical analysis of Pharmacological Effects of Crushing Prasugrel in STEMI Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02212028).
- PharmacoMRI of Parkinson Disease: Complete Statistical AnalysisIndependent statistical analysis of PharmacoMRI of Parkinson Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01528592).
- PHARMSCREENIndependent statistical analysis of Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PHASEIndependent statistical analysis of Effects of Sulforaphane on Normal Prostate Tissue: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00946309).
- Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG): Complete Statistical AnalysisIndependent statistical analysis of Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013): Complete Statistical AnalysisIndependent statistical analysis of Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04711005).
- Phase 1 Study of PBTZ169: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Study of PBTZ169: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03036163).
- Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase 1 Trial of Oral Ixabepilone: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Trial of Oral Ixabepilone: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00632424).
- Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03120832).